Lung Diseases — Effectiveness of Ultra-low-dose Chest CT With AI Based Denoising Solution
Citation(s)
Afadzi M, Fosså K, Andersen HK, Aaløkken TM, Martinsen ACT Image Quality Measured From Ultra-Low Dose Chest Computed Tomography Examination Protocols Using 6 Different Iterative Reconstructions From 4 Vendors, a Phantom Study. J Comput Assist Tomogr. 2020 Jan/Feb;44(1):95-101. doi: 10.1097/RCT.0000000000000947.
Boyd MA U.S. radiation protection: role of national and international recommendations and opportunities for collaboration (harmony, not dissonance). Health Phys. 2015 Feb;108(2):278-82. doi: 10.1097/HP.0000000000000236.
Health Development Center, WHO Health Indicators 2019. Mongolian Health Development Center. http://hdc.gov.mn/media/uploads/202108/Eruul_mendiin_uzuulelt_2020.pdf (accessed Feb 14, 2022).
Kim Y, Kim YK, Lee BE, Lee SJ, Ryu YJ, Lee JH, Chang JH Ultra-Low-Dose CT of the Thorax Using Iterative Reconstruction: Evaluation of Image Quality and Radiation Dose Reduction. AJR Am J Roentgenol. 2015 Jun;204(6):1197-202. doi: 10.2214/AJR.14.13629.
Lee SW, Kim Y, Shim SS, Lee JK, Lee SJ, Ryu YJ, Chang JH Image quality assessment of ultra low-dose chest CT using sinogram-affirmed iterative reconstruction. Eur Radiol. 2014 Apr;24(4):817-26. doi: 10.1007/s00330-013-3090-9. Epub 2014 Jan 18.
Tony M Svahn et al, Dose estimation of ultra-low-dose chest CT to different sized adult patients. European Radiology, 2018
Tsushima E Intraclass correlation coefficient as a reliability index [Japanese]. http://www.hs.hirosaki-u.ac.jp/~pteiki/research/stat/icc.pdf. Accessed 9 Feb 2017.
Zhang M, Qi W, Sun Y, Jiang Y, Liu X, Hong N Screening for lung cancer using sub-millisievert chest CT with iterative reconstruction algorithm: image quality and nodule detectability. Br J Radiol. 2018 Oct;91(1090):20170658. doi: 10.1259/bjr.20170658. Epub 2017 Dec 5.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.